

Non-invasive assessment of fibrosis by Magnetic Resonance Imaging: Validation of a novel index from T1 mapping and diffusion-weighted imaging in animals models and kidney allograft recipients.

L Berchtold ⁽¹⁾; I Friedli⁽²⁾; L A Crowe⁽²⁾; S Moll⁽³⁾; K Hadaya⁽¹⁾; T de Perrot⁽²⁾, C Vesin⁽⁴⁾, PY Martin⁽¹⁾; JP Vallée⁽²⁾; S de Seigneux⁽¹⁾

(1) Division of Nephrology, Geneva University Hospitals, Geneva, Switzerland; (2) Division of Radiology, Geneva University Hospitals, Geneva, Switzerland; (3) Division of Pathology, Geneva University Hospitals, Geneva, Switzerland; (4) Division of Cell Physiology and Metabolism, Geneva University Hospitals, Geneva Switzerland

INTRODUCTION

Renal interstitial fibrosis is a common process to kidney diseases and is predictive of renal prognosis. Therefore, its evaluation is of prime importance in CKD patients.

Interstitial fibrosis is assessed by renal biopsy, an invasive procedure associated with complications, inaccuracies and biais. There is currently no clinically noninvasive tool to evaluate precisely interstitial

RESULTS IN PATIENTS

In order to decrease interindividual variability, we derived a new index expressed as the difference between cortical and medullary $\Delta T1 = T1$ Cortex – T1 medulla values: and $\Delta ADC = ADC \text{ cortex} - ADC \text{ medulla}$

RESULTS: T1

fibrosis.

Diffusion MRI is a new tool to evaluate kidney fibrosis non invasively. Up to now, low image resolution and interindividual variations limited its clinical use.

AIMS AND METHODS OF THE STUDY

To compare a new optimized MRI diffusion sequence called "RESOLVE"^a with T1 mapping to predict interstitial fibrosis (RESOLVE = REadout Segmentation Of Long Variable Echo train).

First, we validated the new sequence in two rat models of fibrosis: unilateral urinary obstruction (UUO) and inflammatory nephritis (IN).

Then, 33 kidney allograft patients undergoing kidney biopsy were examined using MRI: T1 mapping and Diffusion Sequence (RESOLVE)

The association between renal ADC (apparent diffusion coefficient)



Delta T1 correlated to histological fibrosis ($R^2 = 0.29$) and Banff IF/TA.

Delta T1 was not helpful for evaluation of inflammation

RESULTS: RESOLVE

 In kidney allograft patients undergoing biopsy, delta ADC correlated to histological fibrosis percentage as assessed by the pathologist and by automatized methods ($R^2 = 0.64$, P < 0.001).

values and histological fibrosis or inflammation assessment was investigated using Pearson's tests after controlling the linear associations with scatter plots.

Both automated and visual analysis of histological fibrosis were performed.

RESULTS IN RATS MODELS

UUO: unilateral urinary obstruction



In addition, we observed negativization of delta ADC values for patients harboring more than 40% interstitial fibrosis.



Using delta ADC allowed a better correlation to fibrosis and minimized interindividual variation.

> Delta ADC did not discriminate for the severity of inflammation

Delta ADC outperformed Delta T1 with a stronger negative correlation to fibrosis ($R^2 0.64 vs R^2 0.29$).



IN: inflammatory nephritis (BSA)



MOLLI



CONCLUSIONS

Optimized diffusion MRI and delta ADC index appear: - to be useful in assessing the severity of interstitial fibrosis in kidney allograft recipients and CKD patients. - to show promise as a non-invasive and effective technique to guide therapy and follow-up in CKD patients.

REFERENCES

^aImprovement of renal diffusion-weighted magnetic resonance imaging with readout-segmented echo-planar imaging at 3T. I Friedli et al., MRI 2015,

T2 relaxation time and apparent diffusion coefficient for noninvasive assessment of renal pathology after acute kidney injury in mice: comparison with histopathology; Hueper K et Al, Invest Radiol 2013

Noninvasive Evaluation of Kidney Hypoxia and Fibrosis Using Magnetic Resonance Imaging, Inoue T et Al., J Am Nephro, 2011 Assessment of renal fibrosis in chronic kidney disease using diffusion-weighted MRI, Zhao, J et Al. Clin rad 2014

Contact : lena.berchtold@hcuge.ch



Lena Berchtold

Chronic Kidney Disease. Lab methods, GFR measurement, urine proteomics.

DOI: 10.3252/pso.eu.53era.2016





